<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036257</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-461-010</org_study_id>
    <nct_id>NCT00036257</nct_id>
  </id_info>
  <brief_title>Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cell Pathways</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine a maximum tolerated dose and to evaluate the&#xD;
      safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>15</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-461</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed or refractory chronic lymphocytic leukemia.&#xD;
&#xD;
          2. Patients must have either intermediate or high risk chronic lymphocytic leukemia&#xD;
             according to the Rai Staging System.&#xD;
&#xD;
          3. Must have failed at least 1 prior chemotherapy regimen (at least 1 of which included&#xD;
             fludarabine) for CLL.&#xD;
&#xD;
          4. No prior therapy within 4 weeks prior to entering the study. Patients must have fully&#xD;
             recovered from the acute effects of prior therapy.&#xD;
&#xD;
          5. Platelet count = 75,000/mm3 , hemoglobin = 8 gm/dL.&#xD;
&#xD;
          6. Expected remaining life span &gt; or = three months.&#xD;
&#xD;
          7. ECOG performance status 0 - 2.&#xD;
&#xD;
          8. 18 years or of legal age.&#xD;
&#xD;
          9. Male patients or non-pregnant and non-lactating female patients, who are either using&#xD;
             adequate birth control, are surgically sterile or post-menopausal.&#xD;
&#xD;
         10. Negative serum pregnancy test, if fertile female.&#xD;
&#xD;
         11. Willingness and ability to sign an informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of CNS involvement.&#xD;
&#xD;
          2. Other active malignancy or history of treatment of any malignancy (excluding&#xD;
             non-melanoma skin cancer) within the previous three years.&#xD;
&#xD;
          3. Previous therapy with Campath.&#xD;
&#xD;
          4. Patients with low-risk chronic lymphocytic leukemia according to the Rai Staging&#xD;
             System.&#xD;
&#xD;
          5. Concurrent immunotherapy.&#xD;
&#xD;
          6. Concurrent use of steroids.&#xD;
&#xD;
          7. Use of an investigational medication or device within 1 month of initiating study&#xD;
             therapy.&#xD;
&#xD;
          8. Patients who have had allogeneic bone marrow transplantation.&#xD;
&#xD;
          9. Total serum bilirubin above the upper limit of normal; serum creatinine above the&#xD;
             upper limit of normal.&#xD;
&#xD;
         10. AST or ALT &gt; 2.5 times the upper limit of normal.&#xD;
&#xD;
         11. Any condition or any medication which may interfere with the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Centers of Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Regional Cancer Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center (US Oncology)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>May 8, 2002</study_first_submitted>
  <study_first_submitted_qc>May 8, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2002</study_first_posted>
  <last_update_submitted>October 14, 2011</last_update_submitted>
  <last_update_submitted_qc>October 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>CLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

